WET AGE-RELATED MACULAR DEGENERATION
DIABETIC MACULAR EDEMA
DIABETIC RETINOPATHY
NON-INFECTIOUS UVEITIS
DRY AGE-RELATED MACULAR DEGENERATION
RETINAL VEIN OCCLUSION
ADDITIONAL INFORMATION
DFI17940 Study – A Phase 1/2 dose escalation and dose expansion study to evaluate the safety, tolerability, and efficacy of one-time intravitreal dose of SAR402663 in participants with neovascular age-related macular degeneration
4D-150-C004 Study – A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
MK-8748-002 Study – A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2mg) in subjects with neovascular age-related macular degeneration (NVAMD)
ADVM-022-13 Aquarius Study – A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene soroparvovec (Ixo-vec) in Participants with Neovascular Age-Related Macular Degeneration (AQUARIUS)
EYP-1901-304 Capri Study – A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
GR46431 Study – A PHASE I, MULTICENTER, OPEN-LABEL, MULTIPLE-ASCENDING DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF RO7823653 ADMINISTERED BY INTRAVITREAL INJECTION AS MONOTHERAPY AND IN COMBINATION WITH FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA
EYP-1901-303 Como Study – A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
No studies enrolling now
KSMP001-01-S1 Peak – A Multicenter Platform Study on the Safety, Tolerability, Bioactivity, and Pharmacokinetics of Intravitreal Therapies in Retinal Vascular and Inflammatory Diseases
KSMP001-02-S2 Pinnacle – A Multicenter Platform Study on the Safety, Tolerability, Bioactivity, and Pharmacokinetics of Intravitreal Therapies in Retinal Vascular and Inflammatory Diseases
R3918-AMD-2326 Sienna Study – A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration
GR44351 GAllette Study – A Phase IIa, Multicenter, Open-Label, Single-arm Study to Optimize Subretinal Delivery and to Evaluate Safety and Activity of OpRegen in Patients with Genographic Atrophy Secondary to Age-Related Macular Degeneration
APL3007-GA-201 Study – Phase 2, Randomized, Placebo-Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration
DFI18231 Study – A Phase 1/2, study to evaluate the safety, tolerability, and efficacy of one-time intravitreal dose of SAR446597 in participants with geographic atrophy secondary to age-related macular degeneration
CFWY003A12201 Circle Study – A randomized, double masked, placebo-controlled, multicenter, dose range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration
No studies enrolling now
PI Crane: Retina Vitreous Associates of Florida – Tampa, FL
Public Minutes Link: https://ibcminutes.com/FL00640
PI Eichenbaum: Retina Vitreous Associates of Florida – St. Petersburg, FL
Public Minutes Link: https://ibcminutes.com/FL00155